We identified 58 shared therapeutic targets for NAFLD‐DM comorbidity, including HSP90AA1, ESR1, MMP9, EGFR, AKT1, and CASP3. This evidence concerns the gene HSP90AA1 and metabolic dysfunction-associated steatotic liver disease.